CPS
  • Home

Lung Cancer

PD-L1 IHC 28-8 pharmDx Interpretation Training for Non-Small Cell Lung Cancer (NSCLC)​

This three-part self-paced learning program will enable you to confidently interpret PD-L1 expression utilizing PD-L1 IHC 28-8 pharmDx. PD-L1 expression (≥ 1% tumor cell expression) as detected by PD-L1 IHC 28-8 pharmDx in NSCLC may be used as an aid in the assessment of patients for whom nivolumab and ipilimumab combination treatment is being considered. ​

    clockimg 2h
  • Interactive
  • Foundational
 saveimgSave unsaveimgUnsave

 

What you will learn​

 

The PD-L1 IHC 28-8 pharmDx interpretation training is a comprehensive program with in-depth content and practice cases focused on helping pathologists to:​

  • Understand the role of immune checkpoint pathways​
  • Learn about technical considerations for optimal slide staining results​
  • Learn how to evaluate Non-Small Cell Lung Cancer (NSCLC) specimens, stained with PD-L1 IHC 28-8 pharmDx​

​

Review the Intended Use for PD-L1 IHC 28-8 pharmDx SK005.

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​​D0113485_1.00